Arcturus Therapeutics Holdings (ARCT) closed at $11.07 on October 21, 2026, up 0.8% from the previous close, on volume of 317,354 shares (30-day average 733,015).
Data as of October 21, 2026.
Arcturus (ARCT) spotlights Phase 2 OTC data as LUNAR 2.0 shows 40-fold NHP expression gains
Market Chameleon (Thu, 24-Sep 5:03 AM ET)
Business Wire (Wed, 23-Sep 4:01 PM ET)
Business Wire (Fri, 18-Sep 9:00 AM ET)
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Business Wire (Mon, 31-Aug 4:01 PM ET)
Arcturus Strengthens Pipeline as Key Phase 2 Milestones Approach and KOSTAIVE® Rights Return
Market Chameleon (Fri, 7-Aug 7:29 AM ET)
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Business Wire (Thu, 6-Aug 4:01 PM ET)
Business Wire (Tue, 28-Jul 4:01 PM ET)
ARCT-032 Shows Early Signals of Mucus Reduction in Cystic Fibrosis Phase 2 Study
Market Chameleon (Wed, 22-Oct 3:54 AM ET)
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Arcturus Therapeutics Holdings trades on the NASDAQ stock market under the symbol ARCT.
As of October 21, 2026, ARCT stock price climbed to $11.07 with 317,354 million shares trading.
ARCT has a beta of 2.16, meaning it tends to be more sensitive to market movements. ARCT has a correlation of 0.06 to the broad based SPY ETF.
ARCT has a market cap of $314.53 million. This is considered a Small Cap stock.
Last quarter Arcturus Therapeutics Holdings reported $3 million in Revenue and -$.84 earnings per share. This fell short of revenue expectation by $-41,336 and exceeded earnings estimates by $.19.
In the last 3 years, ARCT traded as high as $45.00 and as low as $5.50.
The top ETF exchange traded funds that ARCT belongs to (by Net Assets): ARKG, VTI, IWM, VXF, IWN.
ARCT has underperformed the market in the last year with a price return of -48.5% while the SPY ETF gained +16.3%. However, in the short term, ARCT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +85.4% vs +4.4% return in SPY. But in the last 2 weeks, ARCT shares have been beat by the market, returning -14.8% compared to an SPY return of -0.8%.
ARCT support price is $10.31 and resistance is $11.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARCT shares will trade within this expected range on the day.
